Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

4Tech Brings Regulatory Expertise In-House

This article was originally published in Clinica

Executive Summary

Transcatheter heart valve repair specialist 4Tech Inc. has appointed Paul Cornelison vice-president of regulatory affairs, quality assurance & clinical affairs. Cornelison has over 25 years’ experience in medtech-related regulatory and clinical affairs. More recently, prior to joining 4Tech, he had worked in a couple of transcatheter mitral valve repair companies: CardiAQ Valve Technologies Inc., which was acquired by Edwards Lifesciences in July 2015, and Cardiac Dimensions Inc, one of the earliest percutaneous mitral valve repair companies. Cornelison joins Galway, Ireland-based 4Tech just after the firm raised $29m in a series B financing round to help complete a feasibility study of its TriCinch transcatheter tricuspid valve repair system. The study results will be used to support approval to CE mark the device, said to be the only one fully focused on the tricuspid valve.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT103330

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel